DJ001 is primarily used in research settings as a selective inhibitor of the ALK2 (Activin receptor-like kinase-2) receptor. It has shown potential in studying fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder characterized by abnormal bone formation in muscles, tendons, and ligaments. By inhibiting ALK2, DJ001 helps researchers understand the signaling pathways involved in this condition and explore potential therapeutic strategies. Additionally, it is utilized in preclinical studies to investigate its role in other diseases where ALK2 signaling may be implicated, such as certain cancers and inflammatory conditions. Its specificity makes it a valuable tool for targeted biological research.